Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors.

We have examined the ligand regulation and G protein selectivity of the human cannabinoid CB(1) and CB(2) receptors by an in situ reconstitution technique directly measuring G protein activation. Membranes from Spodoptera frugiperda cells expressing CB(1) and CB(2) receptors were chaotrope extracted to denature endogenous GTP-binding proteins. The ability of the receptors to catalyze the GDP-GTP exchange of each G protein was then examined with purified bovine brain G(i) and G(o). Activation of CB(1) receptors produced a high-affinity saturable interaction for both G(i) and G(o). Agonist stimulation of CB(2) receptors also resulted in a high-affinity saturable interaction with G(i). In contrast, CB(2) receptors did not interact efficiently with G(o). G protein activation was then examined with a diverse group of ligands. For the interaction of CB(2) receptors with G(i), HU210 was the only compound tested that demonstrated maximal activation. In contrast, WIN55,212 (64%), anandamide (42%), and Delta(9)-tetrahydrocannabinol (Delta(9)-THC) (44%) all initiated submaximal levels of G protein activation. For CB(1) receptor-catalyzed activation of G(i), HU210, WIN55,212, and anandamide all elicited maximal activation, whereas Delta(9)-THC (56 +/- 6%) caused only partial G(i) activation. In contrast, only HU210 effected maximal CB(1) stimulation of G(o), with anandamide, WIN55, 212, and Delta(9)-THC all stimulating between 60 and 75% compared with HU210. These data demonstrate that different agonists induce different conformations of the CB(1) receptor, which in turn can distinguish between different G proteins. Our data thus demonstrate agonist-selective G protein signaling by the CB(1) receptor and suggest that therapeutic agents may be designed to regulate individual G protein-signaling pathways selectively.

[1]  A. Gilman,et al.  The guanine nucleotide activating site of the regulatory component of adenylate cyclase. Identification by ligand binding. , 1982, The Journal of biological chemistry.

[2]  P. Sternweis,et al.  Isolation of two proteins with high affinity for guanine nucleotides from membranes of bovine brain. , 1984, The Journal of biological chemistry.

[3]  A. Gilman,et al.  Chromatographic resolution and immunologic identification of the alpha 40 and alpha 41 subunits of guanine nucleotide-binding regulatory proteins from bovine brain. , 1988, The Journal of biological chemistry.

[4]  J. Northup,et al.  Guanine nucleotide binding characteristics of transducin: essential role of rhodopsin for rapid exchange of guanine nucleotides. , 1990, Biochemistry.

[5]  T. Bonner,et al.  Structure of a cannabinoid receptor and functional expression of the cloned cDNA , 1990, Nature.

[6]  D. Brown,et al.  Cannabinoid receptor agonists inhibit Ca current in NG108–15 neuroblastoma cells via a Pertussis toxin‐sensitive mechanism , 1992, British journal of pharmacology.

[7]  K. Mackie,et al.  Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Munro,et al.  Molecular characterization of a peripheral receptor for cannabinoids , 1993, Nature.

[9]  K. Mackie,et al.  Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. , 1993, Molecular pharmacology.

[10]  D. Selley,et al.  In vitro autoradiography of receptor-activated G proteins in rat brain by agonist-stimulated guanylyl 5'-[gamma-[35S]thio]-triphosphate binding. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[11]  K. Mackie,et al.  Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[12]  G. O'neill,et al.  Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. , 1995, Molecular pharmacology.

[13]  K. Mackie,et al.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. , 1995, Molecular pharmacology.

[14]  Z. Vogel,et al.  The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling , 1995, FEBS letters.

[15]  T. Bonner,et al.  A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. , 1996, Molecular pharmacology.

[16]  J. Northup,et al.  Functional Reconstitution in Situ of 5-Hydroxytryptamine2c (5HT2c) Receptors with αq and Inverse Agonism of 5HT2c Receptor Antagonists* , 1996, The Journal of Biological Chemistry.

[17]  Z. Vogel,et al.  ()--Tetrahydrocannabinol Antagonizes the Peripheral Cannabinoid Receptor-mediated Inhibition of Adenylyl Cyclase (*) , 1996, The Journal of Biological Chemistry.

[18]  S. Ikeda,et al.  Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system. , 1996, Molecular pharmacology.

[19]  R. Quock,et al.  delta 9-Tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain. , 1997, European journal of pharmacology.

[20]  M. Glass,et al.  Concurrent Stimulation of Cannabinoid Cb1 and Dopamine D2 Receptors Augments Camp Accumulation in Striatal Neurons: Evidence for a G S Linkage to the Cb1 Receptor , 1997 .

[21]  H. Yamamura,et al.  SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. , 1997, European journal of pharmacology.

[22]  T. Gudermann,et al.  Functional and structural complexity of signal transduction via G-protein-coupled receptors. , 1997, Annual review of neuroscience.

[23]  R. Pertwee Pharmacology of cannabinoid CB1 and CB2 receptors. , 1997, Pharmacology & therapeutics.

[24]  S. Tuc̆ek,et al.  Is the R and R dichotomy real? , 1997, Trends in pharmacological sciences.

[25]  R. Quock,et al.  Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain. , 1997, European journal of pharmacology.

[26]  P. Casellas,et al.  A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1 , 1997, The Journal of Biological Chemistry.

[27]  S. Ikeda,et al.  SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity. , 1998, Molecular pharmacology.

[28]  A. Howlett The CB1Cannabinoid Receptor in the Brain , 1998, Neurobiology of Disease.

[29]  G. Martin,et al.  Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. , 1998, The Journal of pharmacology and experimental therapeutics.

[30]  D. Bonhaus,et al.  Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors , 1998, British journal of pharmacology.

[31]  D. Kendall,et al.  Ligand Binding and Modulation of Cyclic AMP Levels Depend on the Chemical Nature of Residue 192 of the Human Cannabinoid Receptor 1 , 1998, Journal of neurochemistry.

[32]  D. Selley,et al.  Cannabinoid Receptor Agonist Efficacy for Stimulating [35S]GTPγS Binding to Rat Cerebellar Membranes Correlates with Agonist-induced Decreases in GDP Affinity* , 1998, The Journal of Biological Chemistry.

[33]  A. Howlett,et al.  Differential receptor-G-protein coupling evoked by dissimilar cannabinoid receptor agonists. , 1998, Cellular signalling.

[34]  G. Griffin,et al.  Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes. , 1998, The Journal of pharmacology and experimental therapeutics.

[35]  R. Jensen,et al.  The Bombesin Receptor Subtypes Have Distinct G Protein Specificities* , 1999, The Journal of Biological Chemistry.

[36]  C. Hillard,et al.  Relationships Between Ligand Affinities for the Cerebellar Cannabinoid Receptor CB1 and the Induction of GDP/GTP Exchange , 1999, Journal of neurochemistry.